US FDA Wants More ‘Rigor’ In Assessing Survival As An Oncology Safety Endpoint

 
• By Michael McCaughan
  
OS is no longer a reliable as a primary endpoint thanks to substantial improvement in cancer therapies. (Shutterstock)

More from Clinical Trials

More from R&D